Cd10 and e-cad expression in urinary bladder urothelial and squamous cell carcinoma

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 31, Issue 3, 2012, Pages 203-212

  Omran, Ola M ^a  

^a Assiut University   (Egypt)

Author keywords

Cd10; E cadherin; Immunohistochemistry; Squamous cell carcinoma; Urothelial carcinoma

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; UVOMORULIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMIASIS; SQUAMOUS CELL CARCINOMA; STROMA CELL; TRANSITIONAL CELL CARCINOMA; TUMOR CELL;

ADULT; AGED; BIOTIN; CADHERINS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; EGYPT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPRILYSIN; SCHISTOSOMIASIS; STREPTAVIDIN; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84872164542     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v31.i3.20     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Wu G, Keating A. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer. 2006;106:247-257.
3. Eble JN. Tumors of the kidneys and urinary bladder. Mod Pathol. 2009;22(Suppl 2):S1.
4. Xie L, Moroi Y, Tsuji G, Liu M, Hayashida S, Takahara M, Fukagawa S, Takeuchi S, Shan B, Nakahara T, Uchi H, Yokomizo T, Furue M. CD10-bearing fibroblast inhibits matrigel invasive potency of interleukin-1α-producing squamous cell carcinoma by diminishing substance P levels in the tumor microenvironment. Cancer Sci. 2010;101:2570-2578.
5. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000;113:374-382.
6. Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO. CD10 expression in urothelial carcinoma of the bladder. Diagn Pathol. 2009;4:38.
7. Ishimaru F, Mari B, Shipp MA. The type 2 CD10/ neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. Blood. 1997;89:4136-4145.
8. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest. 2000;106:1399-1407.
9. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 2007;20:84-89.
10. Abdou AG. CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis. APMIS. 2007;115:1206-1218.
11. Cutrona G, Leanza N, Ulivi M, Melioli G, Burgio VL, Mazzarello G, Gabutti G, Roncella S, Ferrarini M. Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood. 1999;94:3067-3076.
12. Bilalovic N, Sandstad B, Golouh R, Nesland JM, Selak I, Torlakovic EE. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol. 2004;17:1251-1258.
13. Ogawa H, Iwaya K, Izumi M, Kuroda M, Serizawa H, Koyanagi Y, Mukai K. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol. 2002;33:806-811.
14. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem. 1990;59:237-252.
15. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251:1451-1455.
16. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeichi M, Mori T. Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol. 1991;139:17-23.
17. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Kremers ED, Dinjens WN, Bosman FT. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol. 1997;182:331-338.
18. Gonzalez MA, Pinder SE, Wencyk PM, Bell JA, Elston CW, Nicholson RI, Robertson JF, Blamey RW, Ellis IO. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/ gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol. 1999;187:523-529.
19. Sun W, Herrera GA. E-cadherin expression in invasive urothelial carcinoma. Ann Diagn Pathol. 2004;8:17-22.
20. San Miguel Fraile P, Gómez de María C, Donis Quintairos L, Carrera Vazquez A, Iglesias Martínez P, Barreiro Barbosa MJ. [Expresion of E-cadherin and catenins in urothelial carcinomas]. Actas Urol Esp. 2007;31:355-360.
21. Simionescu C, Mǎrgǎritescu C, Surpǎţeanu M, Mogoantǎ L, Zǎvoi R, Ciurea R, Surlin P, Stepan A. The study of E-cadherine and CD44 immunoexpression in oral squamous cell carcinoma. Rom J Morphol Embryol. 2008;49:189-193.
22. Stepan A, Mǎrgǎritescu C, Simionescu C, Ciurea R. E-cadherin and p63 immunoexpression in dys plastic lesions and urothelial carcinomas of the bladder. Rom J Morphol Embryol. 2009;50:461-465.
23. Seitz M, Zaak D, Knüchel-Clarke R, Stief C. [Urinary bladder tumours. The new 2004 WHO classification]. Urologe A. 2005;44:1073-1086.
24. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 6th ed. Hoboken, New Jersey: John Wiley & Sons; 2002.
25. Paksoy M, Hardal U, Caglar C. Expression of cathepsin D and E-cadherin in primary laryngeal cancers correlation with neck lymph node involvement. J Cancer Res Clin Oncol. 2011;137:1371-1377.
26. Mohkatar N, editor. Cancer pathology registry (1985-1989). 1st ed. Cairo: The National Cancer Institute at Cairo University; 1991.
27. Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between Schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12:97-111.
28. Yasuda M, Itoh J, Satoh Y, Kumaki N, Tsukinoki K, Ogane N, Osamura YR. Availability of CD10 as a histopathological diagnostic marker. Acta Histochem Cytochem 2005;38:17-24.
29. Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol. 2001;14:465-471.
30. Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol. 2002;15:397-405.
31. McIntosh GG, Lodge AJ, Watson P, Hall AG, Wood K, Anderson JJ, Angus B, Horne CH, Milton ID. NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin embedded tissue. Am J Pathol. 1999;154:77-82.
32. Murali R, Delprado W. CD10 Immunohistochemical staining in urothelial neoplasms. Am J Clin Pathol. 2005;124:371-379.
33. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology. 2004;45:460-467.
34. Kim WJ, Park S, Kim YJ. Biomarkers in bladder cancer: present status and perspectives. Biomark Insights. 2007;2:95-105.
35. Stallings-Mann M, Radisky D. Matrix metalloproteinase- induced malignancy in mammary epithelial cells. Cells Tissues Organs. 2007;185:104-110.
36. Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 anti gen expression in diffuse B-cell lymphoma. Am J Clin Pathol. 2001;115:582-588.
37. Shipp MA, Tarr GE, Chen C-Y, Switzer SN, Hersh LB, Stein H, Sunday ME, Reinherz EL. CD10/ neutral endopeptidase 24.11 hydrolyzes bombesinlike peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A. 1991;88:10662-10666.
38. Gohring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J, Riemann D. Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med. 1998;2:409-414.
39. Basset P, Wolf C, Rouyer N, Bellocq JP, Rio MC, Chambon P. Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer. 1994;74:1045-1049.
40. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 1998;83:1153-1162.
41. Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, Lu ZF. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol. 2005;35:245-250.
42. Puri V, Jain M, Thomas S. Stromal expression of CD10 in invasive breast carcinoma and its correlation with ER, PR, HER2-neu, and Ki67. Int J Breast Cancer. 2011:437957.
43. Deniz K, Coban G, Okten T. Anti-CD10 (56C6) expression in soft tissue sarcomas. Pathol Res Pract. 2012;208:281-285.
44. Kuphal S, Bosserhoff AK. E-cadherin cell-cell communication in melanogenesis and during development of malignant melanoma. Arch Biochem Biophys. 2011;524:43-47.
45. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993;5:806-811.
46. Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grübel G, Legrand JF, Als-Nielsen J, Colman DR, Hendrickson WA. Structural basis of cell-cell adhesion by cadherins. Nature. 1995;374:327-337.
47. Ding J, Liao GQ, Zhang ZM, Pan Y, Li DM, Chen HJ, Wang SY, Li Y, Wei N. [Expression and significance of Slug, E-cadherin and N-cadherin in gastrointestinal stromal tumors]. Zhonghua Yi Xue Za Zhi. 2012;92:264-268.
48. Ghoneim MA, EL-Mekresh MM, El-Baz MA, Ashamallah A. Radical cystectomy for carcinoma of the bladder critical evaluation of the results in 1026 cases. J Urol. 1997;158:393-399.